Evidence map›Paper›PMID 27688247›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2017

Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Elizabeth Scarr, Catriona McLean, Brian Dean

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Sex, Age, and Regional Differences inCurrent neuropharmacology · 2023
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Elizabeth ScarrMolecular Psychiatry Laboratory, Division of Biological Psychiatry and Mental Health, Florey Institute for Neuroscience and Mental Health, 30 Royal Parade, Parkville, VIC, 3052, Australia.
Catriona McLeanVictorian Brain Bank Network, Florey Institute for Neuroscience and Mental Health, 30 Royal Parade, Parkville, VIC, 3052, Australia.
Brian DeanMolecular Psychiatry Laboratory, Division of Biological Psychiatry and Mental Health, Florey Institute for Neuroscience and Mental Health, 30 Royal Parade, Parkville, VIC, 3052, Australia. brian.dean@florey.edu.au.ORCID 0000-0001-7773-4473
Florey Institute of Neuroscience and Mental Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been suggest that drugs specifically targeting muscarinic receptors will be useful in treating Alzheimer's disease. We decided to determine if the response to such drugs may be altered, because of changes in the levels of muscarinic receptors in the CNS from subjects with the disorder. We used in situ radioligand binding with autoradiography to measure the levels of [

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAutoradiographyCerebral CortexCohort StudiesFemaleHippocampusHumansMaleMuscarinic AntagonistsPiperidinesPirenzepineRadioligand AssayRadiopharmaceuticalsReceptors, Muscarinic4-diphenylacetoxy-1,1-dimethylpiperidiniumMuscarinic AntagonistsPiperidinesPirenzepineRadiopharmaceuticalsReceptors, MuscarinicTritiumAlzheimer’s diseaseCortexHippocampusMuscarinic receptors

Identifiers

PMID27688247
OpenAlexW2526270177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.